6 Longevity Molecules With Real Science Behind Them: NAC, Urolithin A, Ca-AKG, Taurine, Sulforaphane & Lithium

N-acetylcysteine (NAC), urolithin A, calcium alpha-ketoglutarate (Ca-AKG), taurine, sulforaphane, and low-dose lithium are six naturally occurring or naturally derived compounds studied for the cellular processes that decline with age — glutathione and redox balance, mitochondrial quality control, metabolic and epigenetic signaling, antioxidant-enzyme induction, and neuronal resilience. The evidence is uneven: urolithin A has the most human randomized trials, NAC has well-studied combination data (as GlyNAC), taurine and sulforaphane have strong mechanism work plus selected human trials, and low-dose lithium for aging rests mainly on epidemiology and pre-clinical work. None has been shown to extend human lifespan, and all are discussed here as dietary supplements, not drugs. This guide explains what each one is, how it works, what the trials report, the doses studied, and where the evidence runs out.

Key Takeaways

• N-acetylcysteine (NAC) is a cysteine donor and the rate-limiting precursor for glutathione, the body's master antioxidant; the strongest aging-related human data is for the GlyNAC combination (glycine + NAC), which improved glutathione, oxidative stress, and mitochondrial markers in older adults.
• Urolithin A is a gut-derived metabolite studied as a mitophagy activator; it has the deepest human evidence base of the six, including placebo-controlled RCTs at 500–1000 mg/day.
• Calcium alpha-ketoglutarate (Ca-AKG) is a Krebs-cycle metabolite with striking mouse lifespan and morbidity-compression data; human biological-age trials are early and ongoing.
• Taurine is a conditionally essential amino acid; a 2023 Science paper reported it declines with age and that supplementation extended healthspan in mice and monkeys — but a 2025 human-cohort study found circulating taurine does not reliably decline with age in humans.
• Sulforaphane (from broccoli sprouts) activates Nrf2, inducing phase-II antioxidant and detoxification enzymes; a 12-week RCT reported improved fasting glucose in type 2 diabetes.
• Low-dose lithium (as orotate) is studied for neuronal resilience and longevity signals, but the human evidence is epidemiological and pre-clinical — including a 2025 Nature paper on brain lithium depletion in Alzheimer's — not proven in humans, and therapeutic lithium carries real safety risks.
• These compounds target different hallmarks of aging. None is proven to extend human lifespan or treat disease; all are dietary supplements, and this article is educational, not medical advice.

Why mitochondria, redox balance, and senescence matter for aging

Aging biologists describe the process as a set of interacting "hallmarks of aging" — categories of cellular damage and dysregulation that accumulate over time. A 2025 Cell synthesis on geroscience frames the field's goal as understanding and managing these hallmarks to compress the period of late-life disability. Several of those hallmarks are directly relevant to the six compounds here.

Mitochondrial dysfunction. Mitochondria are the organelles that convert nutrients and oxygen into ATP, the chemical fuel cells run on. With age, the mitochondrial population accumulates damage and turns over more slowly. A 2024 Sports Medicine review frames mitochondria as nutritional targets for preserving muscle and physical function during aging.

Redox imbalance and declining glutathione. Cells continuously generate reactive oxygen species and neutralize them with antioxidant systems, the chief of which is glutathione. Glutathione synthesis depends on the amino acids cysteine (supplied by NAC) and glycine, and intracellular glutathione tends to fall with age. When the balance tips toward oxidative stress, mitochondrial function and proteostasis suffer.

Loss of proteostasis and declining autophagy/mitophagy. Autophagy ("self-eating") is the recycling system that clears damaged proteins and organelles; mitophagy is the branch that targets damaged mitochondria. Both slow with age. Caloric-restriction-mimetic research centers on restoring this housekeeping, and cardiovascular work has emphasized autophagy as a mediator of cardiovascular aging.

Cellular senescence and inflammaging. Senescent cells stop dividing but stay metabolically active, secreting inflammatory signals (the senescence-associated secretory phenotype). They accumulate with age and drive chronic, low-grade inflammation.

Each of the six compounds is studied for one or more of these axes — redox/glutathione (NAC), mitophagy (urolithin A), metabolic and epigenetic signaling (Ca-AKG), multi-hallmark effects including senescence (taurine), Nrf2-driven antioxidant defense (sulforaphane), and neuronal resilience (low-dose lithium). That division of labor is the logic behind discussing them together.

What is N-acetylcysteine (NAC) and does it support healthy aging?

N-acetylcysteine is a stabilized form of the amino acid cysteine. Its central role in the aging conversation is as the rate-limiting precursor for glutathione synthesis: glutathione is built from cysteine, glycine, and glutamate, and cysteine availability is usually the bottleneck. By supplying cysteine, NAC supports the cell's capacity to replenish glutathione and buffer oxidative stress.

Mechanism and the GlyNAC evidence

Most of the aging-specific human data comes not from NAC alone but from GlyNAC — glycine plus NAC, supplying both rate-limiting glutathione precursors together. The work comes largely from Sekhar's group at Baylor.

• Kumar et al., 2021, *Clinical and Translational Medicine* (pilot). An open-label pilot in older adults reported that 24 weeks of GlyNAC corrected glutathione deficiency and improved markers of oxidative stress, mitochondrial fuel oxidation, inflammation, insulin resistance, endothelial function, genotoxicity, muscle strength, and cognition — with several measures regressing toward youthful levels and partially reverting after withdrawal.
• Kumar et al., 2023, *Journals of Gerontology: Series A* (RCT). A randomized clinical trial in older adults reported that 16 weeks of GlyNAC improved glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and several "hallmarks of aging" markers versus comparison.

Honest framing

Two caveats matter. First, the strongest longevity-relevant signal is for the combination (GlyNAC), not NAC in isolation; attributing the full GlyNAC effect to NAC alone overstates the NAC-specific evidence. Second, antioxidant supplementation is context-dependent — more is not always better, and over-suppressing physiological reactive-oxygen signaling can blunt beneficial adaptations (for example, some exercise responses). NAC is best understood as supporting glutathione capacity under conditions of deficiency or oxidative burden, not as a universal antioxidant.

Studied dose: GlyNAC trials dosed NAC and glycine each at roughly 100 mg/kg/day in divided doses; standalone NAC supplementation is commonly used in the ~600–1,200 mg/day range, though that range reflects general use rather than the aging-specific GlyNAC protocol.

What is urolithin A and does it work?

Urolithin A is a postbiotic — a metabolite gut bacteria produce when they digest ellagitannins, the polyphenols in pomegranates, walnuts, and certain berries. A 2022 mechanistic review details how urolithins arise as gut-microbial metabolites of ellagitannins. Not everyone's microbiome makes urolithin A efficiently, so direct supplementation sidesteps that variability.

Mechanism: mitophagy activation

Urolithin A entered the longevity literature in a 2016 Nature Medicine paper showing it induced mitophagy and prolonged lifespan in the worm C. elegans, while improving muscle function in rodents. Mitophagy is the quality-control step that removes damaged mitochondria so healthier ones can take their place; later reviews expand the mechanism.

Human clinical evidence

Urolithin A has the most developed human evidence of the six compounds.

• Andreux et al., 2019, *Nature Metabolism* (first-in-human RCT). Randomized, double-blind, placebo-controlled study of 250, 500, and 1000 mg/day for 28 days in older adults; no significant adverse-event differences from placebo and a plasma signature consistent with improved mitochondrial and cellular health.
• Singh et al., 2022, *Cell Reports Medicine*. Four-month RCT in middle-aged adults at 500 mg/day reporting improvements in muscle strength, exercise performance, and mitochondrial biomarkers.
• Liu et al., 2022, *JAMA Network Open*. Four-month RCT in older adults reporting improved muscle endurance and mitochondrial-health biomarkers versus placebo.
• Denk et al., 2025, *Nature Aging*. A randomized, placebo-controlled trial examining urolithin A's effect on markers of age-related immune decline.

A 2024 systematic review in Ageing Research Reviews synthesizes the human literature, with additional context from a 2023 scoping review, a heart-failure trial, a trained-runner study, and human-microglia mechanistic work.

Studied dose: 500 mg once daily is the most-studied dose.

Limitations: the strongest signals are in muscle and mitochondrial biomarkers; other endpoints are earlier-stage, and biomarker change is not proof of healthspan gain.

What is calcium alpha-ketoglutarate (Ca-AKG)?

Alpha-ketoglutarate (AKG) is a central intermediate of the Krebs cycle — the metabolic loop that extracts energy from glucose, fats, and amino acids. AKG also acts as a cofactor for dioxygenase enzymes that regulate DNA and histone methylation, linking metabolism to epigenetics. The supplement form pairs AKG with calcium for stability. AKG is endogenous, so supplementation studies how added dietary AKG shifts circulating and tissue levels.

Mechanism and pre-clinical evidence

The animal data is the most dramatic of the six compounds. A 2020 Cell Metabolism study reported that Ca-AKG started late in life extended median lifespan and compressed morbidity in mice — they lived longer and spent a greater fraction of life healthy. A 2014 Nature paper established a mechanism in C. elegans: AKG extends lifespan by inhibiting ATP synthase and TOR, a nutrient-sensing longevity pathway. A 2020 *Nature Communications* paper connected AKG to age-related osteoporosis in mice via histone methylation.

Human clinical evidence

Human data is younger. A 2022 Trends in Endocrinology and Metabolism review summarized AKG dietary-supplementation research and open questions. The most-cited human report — Demidenko et al., 2021, in Aging (Albany NY) — was a retrospective analysis of 42 adults taking a Ca-AKG-plus-vitamins formulation for ~7 months, reporting an average ~8-year reduction in biological age on a DNA-methylation clock, but lacking a placebo control. To address that gap, the registered ABLE RCT (Sandalova et al., 2023, GeroScience) tests 1 g/day sustained-release Ca-AKG versus placebo in 120 middle-aged adults with elevated epigenetic age, using DNA-methylation age as the primary outcome.

Studied dose: human protocols commonly use ~1–3 g/day (ABLE uses 1 g/day sustained-release).

Limitations: the headline lifespan data is in mice; the most-cited human study was uncontrolled, and controlled RCTs are still maturing.

What is taurine and does taurine deficiency drive aging?

Taurine is a conditionally essential amino acid — abundant in muscle, brain, and heart, and obtained from diet (especially animal foods) and limited internal synthesis. It is also a well-established essential nutrient with cardiovascular relevance.

The 2023 Science paper — and the 2025 counterpoint

Taurine surged into longevity discussion with Singh et al., 2023, *Science* ("Taurine deficiency as a driver of aging"). The paper reported that circulating taurine declines with age in mice, monkeys, and humans, and that reversing that decline through supplementation extended healthspan and lifespan in mice and improved healthspan markers in monkeys — with taurine reducing cellular senescence, suppressing mitochondrial dysfunction, decreasing DNA damage, and attenuating inflammaging. It is a genuinely multi-hallmark mechanism story.

But the human side of the claim has been challenged. Marcangeli et al., 2025, in *Aging Cell reported that, in human cohorts, circulating taurine levels were not reliably associated with age, muscle mass, strength, physical performance, body composition, insulin sensitivity, or mitochondrial function — directly questioning whether taurine deficiency drives human* aging. We surface this counterpoint deliberately: the mouse-and-monkey data is striking, but the human "does taurine even decline with age?" question is currently contested.

Studied dose: human taurine intake in trials and dietary contexts commonly spans ~1–6 g/day; the longevity hypothesis derives mainly from animal dosing translated to humans, not from human lifespan trials.

Limitations: the lifespan/healthspan extension is in animals; the foundational human premise (age-related decline) is disputed by at least one well-conducted 2025 cohort analysis.

What is sulforaphane and how does it work?

Sulforaphane is an isothiocyanate generated when glucoraphanin (concentrated in broccoli sprouts) meets the enzyme myrosinase. Its signature mechanism is activation of Nrf2 (nuclear factor erythroid 2–related factor 2), a transcription factor that switches on a battery of phase-II antioxidant and detoxification enzymes — the cell's endogenous defense program. Reviews summarize sulforaphane's immunomodulatory and antioxidant activities, and pre-clinical work links sulforaphane to natural-killer-cell function and cytokine production.

Human clinical evidence

The most relevant metabolic/longevity-adjacent human trial is Axelsson et al., 2017, *Science Translational Medicine*: a 12-week randomized, placebo-controlled trial of concentrated broccoli-sprout extract (sulforaphane/glucoraphanin) in patients with type 2 diabetes. The trial reported reduced fasting blood glucose in obese, dysregulated participants, with a mechanism traced to Nrf2-mediated suppression of hepatic gluconeogenesis. This connects sulforaphane's antioxidant-enzyme induction to a concrete human metabolic endpoint.

Studied dose: the Axelsson trial used a concentrated broccoli-sprout extract standardized to sulforaphane/glucoraphanin; sulforaphane bioavailability depends heavily on formulation (active myrosinase, sprout source).

Limitations: much sulforaphane evidence is mechanistic or in specific conditions (e.g., dysglycemia); broad healthy-aging human outcome trials are limited, and bioavailability varies widely between products.

Is low-dose lithium a longevity compound — and is it safe?

Lithium is best known as a prescription mood stabilizer. The longevity interest is in low-dose (trace) lithium — far below psychiatric dosing — and its possible role in neuronal resilience and aging.

The evidence, honestly characterized

• Zarse et al., 2011, *European Journal of Nutrition*. This paper reported two strands: low-dose lithium extended lifespan in C. elegans, and an epidemiological association in which higher lithium concentrations in Japanese municipal drinking water correlated with lower all-cause mortality across 18 municipalities. The human signal is a population correlation, not a controlled trial — it cannot establish causation.
• Aron et al. (Yankner lab), 2025, *Nature*. A high-profile study reporting that endogenous brain lithium is depleted early in Alzheimer's pathology; in mouse models, reducing cortical lithium increased amyloid-? and phospho-tau and accelerated cognitive decline, while replenishing lithium with lithium orotate reversed pathology and restored memory — even in older mice. This is compelling pre-clinical and human-tissue work, not a demonstration that lithium-orotate supplements prevent dementia in people.

Critical safety framing

This compound demands caution. Therapeutic lithium is a prescription drug with a narrow therapeutic margin — the gap between an effective dose and a toxic one is small, and chronic use is monitored for thyroid and kidney effects. Lithium-orotate supplements are dosed far lower (typically a few milligrams of elemental lithium), but the longevity and neuroprotective evidence in humans is preliminary — epidemiological and pre-clinical, not proven. Anyone considering low-dose lithium should consult a physician first, and it is especially important for people who are pregnant or nursing, who have thyroid or kidney conditions, or who take psychiatric, cardiac, or renal medications (including NSAIDs, ACE inhibitors, and diuretics, which can raise lithium levels). Do not self-treat a mood or neurological condition with supplemental lithium.

Studied dose: the epidemiological signal involved trace water-borne lithium; supplemental lithium orotate is low-dose. There is no validated human longevity dose.

How do the six molecules compare?

How to think about stacking these compounds

A few honest framings.

First, the foundations come before any supplement. No compound here substitutes for sleep, resistance training, whole-food nutrition, alcohol moderation, and stress management. The supplement literature is most useful as a layer on top of those, not a replacement.

Second, they target different hallmarks — which is the case for thinking of them together. NAC supports redox/glutathione capacity, urolithin A targets mitophagy, Ca-AKG addresses metabolic and epigenetic signaling, taurine acts across several hallmarks (in animals), sulforaphane drives Nrf2 antioxidant defense, and low-dose lithium is studied for neuronal resilience. Because these are distinct mechanisms, they are non-redundant in principle.

Third, single-compound studies do not predict multi-compound effects. Nearly every RCT cited above tested a compound alone (GlyNAC being a deliberate combination). The interactions of six compounds together, at human doses, over years, are essentially unstudied. That is a real gap.

Fourth, more antioxidant is not always better. NAC and sulforaphane both act on redox biology; excessive antioxidant load can theoretically blunt beneficial reactive-oxygen signaling (such as some exercise adaptations). The aim is supporting endogenous defense capacity, not maximally suppressing all oxidation.

Fifth, lithium is the cautious one. Even at low doses, lithium interacts with thyroid, kidney, and several drug classes. It warrants individualized medical guidance in a way the other five generally do not.

How does this compare to NMN and NAD+ boosters?

NMN (nicotinamide mononucleotide) raises NAD+ via the salvage pathway, supporting sirtuin and PARP signaling — a different axis from the six molecules here. The NMN human base includes a randomized safety study in GeroScience and a 2021 Science trial reporting improved muscle insulin sensitivity in prediabetic women. The useful question is not "which compound is best" but "which cellular mechanism do I want to support, with what evidence?" Broad reviews of the anti-aging landscape cover both axes.

What the research does NOT say

To be explicit about the limits:

• No human lifespan extension. Direct lifespan-extension evidence in humans requires multi-decade trials not completed for any of these compounds. The lifespan data is in mice and worms.
• These are supplements, not disease treatments. Structure/function research is the correct frame; therapeutic or disease-cure claims are not supported. The 2025 lithium-Alzheimer's work is pre-clinical and human-tissue, not evidence that lithium supplements prevent dementia.
• The taurine human premise is contested. A 2025 cohort analysis found circulating taurine did not reliably decline with age in humans, undercutting a key plank of the 2023 hypothesis.
• GlyNAC ≠ NAC alone. The strongest aging-related NAC data is for the glycine + NAC combination, not standalone NAC.
• Biomarker improvements are not proof of healthspan gains. A change in glutathione, mitochondrial-DNA copy number, fasting glucose, or a methylation clock is encouraging but does not guarantee a longer or healthier life.
• Animal effect sizes do not transfer cleanly to humans, and lithium especially carries a narrow safety margin that demands medical oversight.

A fair summary: the published evidence supports the hypothesis that these compounds support specific cellular and tissue functions; it does not yet support strong claims about long-term human health outcomes.

Frequently Asked Questions

Is NAC the same as taking glutathione, and does it help aging? NAC is a precursor: it supplies cysteine, the rate-limiting building block for glutathione, rather than being glutathione itself. The strongest aging-related human data comes from the GlyNAC combination (glycine + NAC), which improved glutathione, oxidative stress, and mitochondrial markers in older adults. NAC alone has less aging-specific human outcome data.

What dose of urolithin A is supported by research? Human RCTs have used 250, 500, and 1000 mg once daily; 500 mg/day is the most-studied dose in middle-aged and older adults across longer trials.

Does calcium alpha-ketoglutarate (Ca-AKG) have human trials? Human evidence is early. The most-cited human report is an uncontrolled biomarker study suggesting reduced epigenetic age, and a registered placebo-controlled RCT (ABLE) of 1 g/day Ca-AKG is underway. The dramatic lifespan and morbidity-compression data is in mice.

Does taurine really decline with age and reverse aging? A 2023 Science paper reported taurine declines with age and that supplementation extended healthspan in mice and monkeys. However, a 2025 human-cohort study found circulating taurine did not reliably decline with age in humans, challenging that premise. The animal data is strong; the human picture is contested.

What does sulforaphane actually do in the body? Sulforaphane activates Nrf2, a transcription factor that switches on the body's own phase-II antioxidant and detoxification enzymes. A 12-week randomized trial of concentrated broccoli-sprout extract reported improved fasting glucose in type 2 diabetes via reduced hepatic glucose production.

Is low-dose lithium safe to take as a supplement? Low-dose lithium orotate supplies far less lithium than prescription doses, but the longevity and brain-health evidence in humans is preliminary — epidemiological and pre-clinical. Lithium has a narrow therapeutic margin and interacts with thyroid, kidney, and several drug classes, so consult a physician first — especially if pregnant, nursing, or taking psychiatric, cardiac, or renal medications.

How are these different from NMN or NAD+ boosters? NMN raises NAD+ to support sirtuin and PARP signaling — a separate mechanism from glutathione, mitophagy, Krebs-cycle metabolism, Nrf2 defense, or neuronal lithium. The approaches are complementary rather than interchangeable.

Are these "anti-aging drugs"? No. They are dietary supplements (and, in lithium's case, a low-dose form of a compound that is also a prescription drug at higher doses). The U.S. Food and Drug Administration has not evaluated structure/function statements for the prevention, diagnosis, treatment, or cure of any disease.

References

1. Kumar P, Liu C, Hsu JW, et al. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clinical and Translational Medicine. 2021. PMID: 33783984. https://pubmed.ncbi.nlm.nih.gov/33783984/
2. Kumar P, Liu C, Suliburk J, et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The Journals of Gerontology: Series A. 2023. PMID: 35975308. https://pubmed.ncbi.nlm.nih.gov/35975308/
3. Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019. PMID: 32694802. https://pubmed.ncbi.nlm.nih.gov/32694802/
4. Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022. PMID: 35584623. https://pubmed.ncbi.nlm.nih.gov/35584623/
5. Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022. PMID: 35050355. https://pubmed.ncbi.nlm.nih.gov/35050355/
6. Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 2016. PMID: 27400265. https://pubmed.ncbi.nlm.nih.gov/27400265/
7. D'Amico D, Andreux PA, Valdés P, Singh A, Rinsch C, Auwerx J. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends in Molecular Medicine. 2021. PMID: 34030963. https://pubmed.ncbi.nlm.nih.gov/34030963/
8. Kuerec AH, Lim XK, Khoo AL, et al. Targeting aging with urolithin A in humans: A systematic review. Ageing Research Reviews. 2024. PMID: 39002645. https://pubmed.ncbi.nlm.nih.gov/39002645/
9. Kothe B, Klein S, Petrosky SN. Urolithin A as a Potential Agent for Prevention of Age-Related Disease: A Scoping Review. Cureus. 2023. PMID: 37637627. https://pubmed.ncbi.nlm.nih.gov/37637627/
10. Faitg J, D'Amico D, Rinsch C, Singh A. Mitophagy Activation by Urolithin A to Target Muscle Aging. Calcified Tissue International. 2024. PMID: 37925671. https://pubmed.ncbi.nlm.nih.gov/37925671/
11. Hasheminezhad SH, Boozari M, Iranshahi M, et al. A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins. Phytotherapy Research. 2022. PMID: 34542202. https://pubmed.ncbi.nlm.nih.gov/34542202/
12. Denk D, Singh A, Kasler HG, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. 2025. PMID: 41174221. https://pubmed.ncbi.nlm.nih.gov/41174221/
13. Jamialahmadi T, Hasanpour M, Vakilian F, et al. Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Placebo-Controlled Trial. Reviews on Recent Clinical Trials. 2024. PMID: 38415449. https://pubmed.ncbi.nlm.nih.gov/38415449/
14. Whitfield J, McKay AKA, Tee N, et al. Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Runners. Sports Medicine. 2025. PMID: 40839339. https://pubmed.ncbi.nlm.nih.gov/40839339/
15. Madsen HB, Navarro C, Gasparini E, et al. Urolithin A and nicotinamide riboside differentially regulate innate immune defenses and metabolism in human microglial cells. Frontiers in Aging Neuroscience. 2024. PMID: 39665042. https://pubmed.ncbi.nlm.nih.gov/39665042/
16. Asadi Shahmirzadi A, Edgar D, Liao CY, et al. Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice. Cell Metabolism. 2020. PMID: 32877690. https://pubmed.ncbi.nlm.nih.gov/32877690/
17. Gyanwali B, Lim ZX, Soh J, et al. Alpha-Ketoglutarate dietary supplementation to improve health in humans. Trends in Endocrinology and Metabolism. 2022. PMID: 34952764. https://pubmed.ncbi.nlm.nih.gov/34952764/
18. Chin RM, Fu X, Pai MY, et al. The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 2014. PMID: 24828042. https://pubmed.ncbi.nlm.nih.gov/24828042/
19. Wang Y, Deng P, Liu Y, et al. Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. Nature Communications. 2020. PMID: 33154378. https://pubmed.ncbi.nlm.nih.gov/33154378/
20. Demidenko O, Barardo D, Budovskii V, et al. Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. Aging (Albany NY). 2021. PMID: 34847066. https://pubmed.ncbi.nlm.nih.gov/34847066/
21. Sandalova E, Goh J, Lim ZX, et al. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol. GeroScience. 2023. PMID: 37217632. https://pubmed.ncbi.nlm.nih.gov/37217632/
22. Singh P, Gollapalli K, Mangiola S, et al. Taurine deficiency as a driver of aging. Science. 2023. PMID: 37289866. https://pubmed.ncbi.nlm.nih.gov/37289866/
23. Marcangeli V, Cefis M, Hammad R, et al. Experimental Evidence Against Taurine Deficiency as a Driver of Aging in Humans. Aging Cell. 2025. PMID: 41061678. https://pubmed.ncbi.nlm.nih.gov/41061678/
24. Axelsson AS, Tubbs E, Mecham B, et al. Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Science Translational Medicine. 2017. PMID: 28615356. https://pubmed.ncbi.nlm.nih.gov/28615356/
25. Mahn A, Castillo A. Potential of Sulforaphane as a Natural Immune System Enhancer: A Review. Molecules. 2021. PMID: 33535560. https://pubmed.ncbi.nlm.nih.gov/33535560/
26. Mazarakis N, Anderson J, Toh ZQ, et al. Examination of Novel Immunomodulatory Effects of L-Sulforaphane. Nutrients. 2021. PMID: 33673203. https://pubmed.ncbi.nlm.nih.gov/33673203/
27. Thejass P, Kuttan G. Augmentation of natural killer cell and antibody-dependent cellular cytotoxicity in BALB/c mice by sulforaphane. Immunopharmacology and Immunotoxicology. 2006. PMID: 16997793. https://pubmed.ncbi.nlm.nih.gov/16997793/
28. Amin PJ, Shankar BS. Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis. Life Sciences. 2015. PMID: 25721293. https://pubmed.ncbi.nlm.nih.gov/25721293/
29. Zarse K, Terao T, Tian J, Iwata N, Ishii N, Ristow M. Low-dose lithium uptake promotes longevity in humans and metazoans. European Journal of Nutrition. 2011. PMID: 21301855. https://pubmed.ncbi.nlm.nih.gov/21301855/
30. Aron L, Ngian ZK, Qiu C, et al. Lithium deficiency and the onset of Alzheimer's disease. Nature. 2025. PMID: 40770094. https://pubmed.ncbi.nlm.nih.gov/40770094/
31. Yi L, Maier AB, Tao R, et al. The efficacy and safety of ?-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023. PMID: 36482258. https://pubmed.ncbi.nlm.nih.gov/36482258/
32. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PMID: 33888596. https://pubmed.ncbi.nlm.nih.gov/33888596/
33. Partridge L, Fuentealba M, Kennedy BK. The quest to slow ageing through drug discovery. Nature Reviews Drug Discovery. 2020. PMID: 32467649. https://pubmed.ncbi.nlm.nih.gov/32467649/
34. Guarente L, Sinclair DA, Kroemer G. Human trials exploring anti-aging medicines. Cell Metabolism. 2024. PMID: 38181790. https://pubmed.ncbi.nlm.nih.gov/38181790/
35. Broome SC, Whitfield J, Karagounis LG, Hawley JA. Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing. Sports Medicine. 2024. PMID: 39060742. https://pubmed.ncbi.nlm.nih.gov/39060742/
36. Madeo F, Carmona-Gutierrez D, Hofer SJ, Kroemer G. Caloric Restriction Mimetics against Age-Associated Disease: Targets, Mechanisms, and Therapeutic Potential. Cell Metabolism. 2019. PMID: 30840912. https://pubmed.ncbi.nlm.nih.gov/30840912/
37. Abdellatif M, Sedej S, Carmona-Gutierrez D, Madeo F, Kroemer G. Autophagy in Cardiovascular Aging. Circulation Research. 2018. PMID: 30355077. https://pubmed.ncbi.nlm.nih.gov/30355077/
38. Liberale L, Tual-Chalot S, Sedej S, et al. Roadmap for alleviating the manifestations of ageing in the cardiovascular system. Nature Reviews Cardiology. 2025. PMID: 39972009. https://pubmed.ncbi.nlm.nih.gov/39972009/
39. Kroemer G, Maier AB, Cuervo AM, Gladyshev VN, Ferrucci L, Gorbunova V. From geroscience to precision geromedicine: Understanding and managing aging. Cell. 2025. PMID: 40250404. https://pubmed.ncbi.nlm.nih.gov/40250404/

Published by the SciRouter Editorial Team for general educational purposes. Last updated June 2026.

Medical & regulatory disclaimer. This article is for educational purposes only and is not medical advice. The compounds discussed are dietary supplements; lithium is also a prescription drug at therapeutic doses and carries a narrow safety margin. These statements have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before starting any supplement, especially if you are pregnant, nursing, have a medical condition (including thyroid or kidney conditions), or take prescription medication.

The six molecules profiled above — N-acetylcysteine, urolithin A, Ca-AKG, taurine, sulforaphane, and low-dose lithium — are the research-backed compounds behind Ares, SciRouter's human-longevity formula. Ares is dosed at levels consistent with the published literature described in this educational guide.

Related reading: Human Longevity in 2026: What the Latest Science Really Says About Living Longer.